Literature DB >> 32496342

Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality.

Donghee Kim1, Luis Miguel Vazquez-Montesino2, Jessica A Escober1, Christopher T Fernandes1, George Cholankeril1, Rohit Loomba3,4, Stephen A Harrison5,6, Zobair M Younossi7, Aijaz Ahmed1.   

Abstract

INTRODUCTION: Higher levels of thyroid-stimulating hormone (TSH) in the euthyroid state can negatively affect the metabolic health, including nonalcoholic fatty liver disease (NAFLD). We studied the effect of TSH levels in the setting of normal levels of thyroid hormone on all-cause and cause-specific mortality stratified by NAFLD status.
METHODS: The National Health and Nutrition Examination Survey (NHANES) III from 1988 to 1994 and NHANES III-linked mortality data through 2015 were used. NAFLD was defined as ultrasonographically diagnosed hepatic steatosis without coexisting liver diseases. Subclinical hypothyroidism was defined as a TSH level over 4.5 mIU/L and "low-normal" thyroid function as higher TSH level (2.5-4.5 mIU/L) within the euthyroid reference range. The Cox proportional hazard model analyzed the all-cause mortality and cause-specific mortality.
RESULTS: In a multivariate logistic regression analysis, individuals with low thyroid function demonstrated an association with NAFLD in a dose-dependent manner. During a median follow-up of 23 years, low thyroid function was associated with increased all-cause mortality only in the univariate model. Low thyroid function was associated with a higher risk for all-cause mortality in individuals with NAFLD and not in those without NAFLD. Furthermore, low thyroid function was associated with a higher risk for cardiovascular mortality in the entire population and among those with NAFLD but demonstrated no association with the non-NAFLD group. DISCUSSION: In this large nationally representative sample of American adults, low thyroid function was associated with NAFLD and a predictor of higher risk for all-cause and cardiovascular mortality in individuals with NAFLD.

Entities:  

Year:  2020        PMID: 32496342     DOI: 10.14309/ajg.0000000000000654

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Nonalcoholic fatty liver disease in early life and all-cause and cause-specific mortality.

Authors:  Donghee Kim; Aijaz Ahmed
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

Review 2.  Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences.

Authors:  Armando Tripodi; Rosa Lombardi; Massimo Primignani; Vincenzo La Mura; Flora Peyvandi; Anna L Fracanzani
Journal:  Biomedicines       Date:  2022-01-24

3.  Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.

Authors:  Stephen A Harrison; Mustafa Bashir; Sam E Moussa; Kevin McCarty; Juan Pablo Frias; Rebecca Taub; Naim Alkhouri
Journal:  Hepatol Commun       Date:  2021-01-04

Review 4.  Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.

Authors:  Maria Mavromati; François R Jornayvaz
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

5.  Interaction Mechanisms Between Major Depressive Disorder and Non-alcoholic Fatty Liver Disease.

Authors:  Qi Shao; Yiping Wu; Jing Ji; Tian Xu; Qiaoyu Yu; Chongyang Ma; Xuejing Liao; Fafeng Cheng; Xueqian Wang
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

6.  Folate Status and Mortality in US Adults With Diabetes: A Nationally Representative Cohort Study.

Authors:  Hui Xiong; Xiaoxiao Li; Shuxian Cheng; Pengyu Chen; Sixu Guo; Xianli Huang; Yu Lu
Journal:  Front Cardiovasc Med       Date:  2022-04-25

Review 7.  Influence of Altered Thyroid Hormone Mechanisms in the Progression of Metabolic Dysfunction Associated with Fatty Liver Disease (MAFLD): A Systematic Review.

Authors:  Rafael Aguiar Marschner; Fernanda Arenhardt; Rafael Teixeira Ribeiro; Simone Magagnin Wajner
Journal:  Metabolites       Date:  2022-07-22

8.  Mediating effect analysis of visceral adiposity index on free triiodothyronine to free thyroxine ratio and non-alcoholic fatty liver disease in euthyroid population.

Authors:  Huan-Xin Liu; Yan-Yan Ren; Cui-Qiao Meng; Zhong Li; Qian Nie; Chun-Hong Yu; Hui-Juan Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

9.  Risk of Liver Fibrosis According to TSH Levels in Euthyroid Subjects.

Authors:  Alba Martínez-Escudé; Guillem Pera; Lluís Rodríguez; Ingrid Arteaga; Carmen Expósito-Martínez; Pere Torán-Monserrat; Llorenç Caballería
Journal:  J Clin Med       Date:  2021-03-25       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.